000167631 001__ 167631
000167631 005__ 20240229133544.0
000167631 0247_ $$2doi$$a10.1002/ijc.33522
000167631 0247_ $$2pmid$$apmid:33634860
000167631 0247_ $$2ISSN$$a0020-7136
000167631 0247_ $$2ISSN$$a1097-0215
000167631 0247_ $$2altmetric$$aaltmetric:102576984
000167631 037__ $$aDKFZ-2021-00465
000167631 041__ $$aEnglish
000167631 082__ $$a610
000167631 1001_ $$0P:(DE-He78)78a9df7108a5b079145be1cb1ab6a315$$aKrilaviciute, Agne$$b0$$eFirst author$$udkfz
000167631 245__ $$aLow positive predictive value of computed tomography screening for lung cancer irrespective of commonly employed definitions of target population.
000167631 260__ $$aBognor Regis$$bWiley-Liss$$c2021
000167631 3367_ $$2DRIVER$$aarticle
000167631 3367_ $$2DataCite$$aOutput Types/Journal article
000167631 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1625048852_23645
000167631 3367_ $$2BibTeX$$aARTICLE
000167631 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000167631 3367_ $$00$$2EndNote$$aJournal Article
000167631 500__ $$a#EA:C070#LA:C070# / 149(1):58-65
000167631 520__ $$aScreening for lung cancer (LC) by low-dose computed tomography (LDCT) has been demonstrated to reduce LC mortality in randomized clinical trials (RCTs), and its implementation is in preparation in many countries. However, definition of the target population, which was based on various combinations of age ranges and definitions of heavy smoking in the RCTs, is subject to ongoing debate. Using epidemiological data from Germany, we aimed to estimate prevalence of preclinical LC and positive predictive value (PPV) of LDCT in potential target populations defined by age and smoking history. Populations aged 50-69, 55-69, 50-74 and 55-79 years were considered in this analysis. Sex-specific prevalence of preclinical LC was estimated using LC incidence data within those age ranges and annual transition rates from preclinical to clinical LC obtained by meta-analysis. Prevalence of preclinical LC among heavy smokers (defined by various pack-year thresholds) within those age ranges was estimated by combining LC prevalence in the general population with proportions of heavy smokers and relative risks for LC among them derived from epidemiological studies. PPVs were calculated by combining these prevalences with sensitivity and specificity estimates of LDCT. Estimated prevalence of LC was 0.3-0.5% (men) and 0.2-0.3% (women) in the general population and 0.8-1.7% in target populations of heavy smokers. Estimates of PPV of LDCT were <20% for all definitions of target populations of heavy smokers. Refined preselection of target populations would be highly desirable to increase PPV and efficiency of LDCT screening and to reduce numbers of false positive LDCT findings.
000167631 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000167631 588__ $$aDataset connected to CrossRef, PubMed,
000167631 650_7 $$2Other$$alung cancer
000167631 650_7 $$2Other$$apack-years
000167631 650_7 $$2Other$$apreclinical cancer
000167631 650_7 $$2Other$$apredictive value
000167631 650_7 $$2Other$$ascreening
000167631 7001_ $$0P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aBrenner, Hermann$$b1$$eLast author$$udkfz
000167631 773__ $$0PERI:(DE-600)1474822-8$$a10.1002/ijc.33522$$gp. ijc.33522$$n1$$p58-65$$tInternational journal of cancer$$v149$$x1097-0215$$y2021
000167631 909CO $$ooai:inrepo02.dkfz.de:167631$$pVDB
000167631 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)78a9df7108a5b079145be1cb1ab6a315$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000167631 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000167631 9130_ $$0G:(DE-HGF)POF3-313$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vCancer risk factors and prevention$$x0
000167631 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000167631 9141_ $$y2021
000167631 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2020-08-32$$wger
000167631 915__ $$0StatID:(DE-HGF)3001$$2StatID$$aDEAL Wiley$$d2020-08-32$$wger
000167631 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bINT J CANCER : 2018$$d2020-08-32
000167631 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2020-08-32
000167631 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2020-08-32
000167631 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2020-08-32
000167631 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2020-08-32
000167631 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2020-08-32
000167631 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2020-08-32
000167631 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2020-08-32
000167631 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2020-08-32
000167631 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2020-08-32
000167631 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2020-08-32
000167631 9201_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie und Alternf.$$x0
000167631 9201_ $$0I:(DE-He78)C120-20160331$$kC120$$lPräventive Onkologie$$x1
000167631 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x2
000167631 980__ $$ajournal
000167631 980__ $$aVDB
000167631 980__ $$aI:(DE-He78)C070-20160331
000167631 980__ $$aI:(DE-He78)C120-20160331
000167631 980__ $$aI:(DE-He78)HD01-20160331
000167631 980__ $$aUNRESTRICTED